‘Manual’ Labor May Boost Inhaled Remodulin’s Chances
This article was originally published in The Pink Sheet Daily
Executive Summary
United Therapeutics hopes plainer instructions will alleviate doctor and patient worry over tricky device-drug combination.
You may also be interested in...
FDA Approves Adcirca (Tadalafil) For PAH; United Therapeutics Ready For U.S. Launch
Tadalafil benefit to clinical worsening claim made it into labeling, but not into the indication.
FDA Approves Adcirca (Tadalafil) For PAH; United Therapeutics Ready For U.S. Launch
Tadalafil benefit to clinical worsening claim made it into labeling, but not into the indication.
New Drug Approvals & Regulatory Updates, In Brief
Solvay's swine-based pancreatic enzyme product approved with REMS: On May 1 FDA granted Solvay Pharmaceuticals' Creon (pancrelipase) the first pancreatic enzyme insufficiency product approval under guidelines that bring the previously unregulated remedies under the FDA umbrella. At the same time the agency made clear its concerns for the class by requiring that CREON have a Risk Evaluation and Mitigation Strategy. As part of the classwide REMS, caregivers and patients are to receive a Medication Guide with dosing and safety information that emphasize the risk of fibrosing colonopathy, a rare adverse reaction in cystic fibrosis patients taking high doses of pancreatic enzyme replacement therapy, as well as the dangers of over- or under-dosing. It also notes the theoretical risk of cross-species infection with porcine viruses because Creon and similar products are derived from pig pancreases (1"The Pink Sheet," Dec. 8, 2008, p. 6). FDA-approved Creon will be available in the third quarter, but the 20-year-old currently marketed formulation will remain available until the launch, the company said